Table. 4 Cost-effectiveness results when CV outcomes are extended until treatment switch (per average patient)
Parameters | Empagliflozin + SoC | Sitagliptin + SoC | Liraglutide + SoC |
|---|---|---|---|
LY (years) | 10.673 | 9.901 | 10.466 |
QALY (years) | 7.621 | 7.057 | 7.411 |
Costs (RMB) | 405,148 | 362,652 | 476,575 |
Incremental LY (years) | Â | 0.772 | 0.207 |
Incremental QALY (years) | Â | 0.564 | 0.211 |
Incremental total cost (RMB) |  | 42,497 | − 71,427 |
ICER (RMB/LY) | Â | 55,047 | Dominant |
ICUR (RMB/QALY) | Â | 75,349 | Dominant |